Strong growth for all Terumo's businesses
This article was originally published in Clinica
Executive Summary
The Japanese company Terumo described the year as being one of "considerable progress", despite unstable exchange rates, further regulation of medical fees and increased competition. The company has ambitious plans to boost turnover to become a ¥00 billion ($1.5 billion) company within three years. In the year ended March 31 1997, the company's annual sales rose 14% to Yen138 billion ($1.1 billion), and net income rocketed 289% to Yen12.5 billion.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.